Epocrates Drug Updates - Editor's Pick

No Editor's Pick this week.

Noteworthy Recent Updates

July 24, 2015
FDA MedWatch Safety Alert for Proglycem
The FDA is warning that infants and newborns treated with Proglycem (diazoxide) for hypoglycemia may develop pulmonary HTN. The agency has identified 11 cases of pulmonary HTN in infants and newborns treated with diazoxide since its approval in 1973. Clinicians should closely monitor babies receiving Proglycem, especially those with risk factors for pulmonary HTN. If pulmonary HTN is identified, Proglycem should be discontinued.
Proglycem

July 24, 2015
Kybella Approved for Submental Fat
Kybella (deoxycholic acid) is the first injectable treatment available to improve the appearance of fullness associated with submental fat. The drug is indicated for the reduction of moderate to severe submental fat convexity and is administered as up to 50 SC injections per treatment. The safe and effective use of Kybella for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.
Kybella

July 24, 2015
FDA MedWatch Safety Alert for NSAIDs
The FDA is strengthening an existing warning that non-aspirin NSAIDs increase MI and stroke risk. MI and stroke risk may occur within the first weeks of NSAID treatment, and risk may increase with higher doses or longer treatment duration. Advise patients to use the lowest effective amount for the shortest effective treatment duration, and to seek immediate medical attention if cardiac signs or symptoms occur.
Epocrates Online

July 13, 2015
FDA MedWatch Safety Alert for Codeine in Pediatric Patients
The FDA is investigating the safety of codeine-containing cough-and-cold products in pediatric patients due to risk of serious adverse effects, including respiratory depression. In April 2015, the European Medicines Agency (EMA) warned that codeine use for cough and cold is now contraindicated in patients.
codeine/guaifenesin Glatopa

July 6, 2015
Glatopa Available for Multiple Sclerosis
Glatopa (glatiramer) is the first branded generic available for Copaxone for the treatment of relapsing forms of multiple sclerosis. The drug is available in a 1-mL, 20-mg/mL injection for once-daily subcutaneous use. The 20-mg/mL dosage form is not additive or interchangeable with the Copaxone 40-mg/mL dosage form. Glatopa should not be used in patients with a hypersensitivity to glatiramer or mannitol.
Glatopa

New Drug Monographs

No new drug monographs this week.

What is an RSS Feed?

From Wikipedia: "RSS is a simple XML-based system that allows users to subscribe to their favorite websites. Using RSS, webmasters can put their content into a standardized format, which can be viewed and organized through RSS-aware software or automatically conveyed as new content on another website."

email Subscribe by email

Enter your email address:


   Cancel

Delivered by FeedBurner

Erratum

June 18, 2015
The Hemangeol monograph has been updated to correct the duration of the Start dosing for infantile hemangioma in patients 5 weeks to 5 months old. Hemangeol should be started at a dose of 0.15 mL/kg PO bid x1wk, then 0.3 mL/kg PO bid x1wk. Please update your Epocrates app regularly to ensure that you always have the latest content.